贝叶斯主动学习辅助基于结构的虚拟查揭示了突变IDH1的新型抑制剂
Sen Xu1, Yue Yang1, Chao Chen1
1Xinyang Vocational and Technical College, Xinyang City, 464000, Henan Province, China.
Molecular diversity
|October 15, 2025
概括
研究人员开发了一种结合人工智能和虚拟查的新方法,以发现突变异位酸脱酶1 (IDH1) 的选择性抑制剂. 这种方法加速了对IDH1驱动的癌症有前途的候选药物的鉴定.
科学领域:
- 药用化学 医学化学
- 计算机化药物发现技术
- 在瘤学瘤学.
背景情况:
- 异酸脱酶1 (IDH1) 中的突变是某些癌症的关键驱动因素,产生基代谢物2 - 基酸盐.
- 用选择性小分子抑制剂向突变IDH1是一种有前途的治疗策略.
研究的目的:
- 开发和验证一个双策略管道,将贝叶斯神经网络 (BNN) 辅助的基于结构的虚拟选 (SBVS) 与主动学习引导的生成设计集成在一起.
- 加速发现新型,化学多样化和可开发的选择性突变IDH1抑制剂.
主要方法:
- 在约310万个候选结构上使用BNN进行活动预测和不确定性量化.
- 采用基于变压器的生成模型用于架构多样化的模拟设计,优化结合亲和力,物理化学性质和ADMET.
- 进行了共识对接,分子动力学 (MD) 模拟,自由能量分解,以及用于化合物评估的in silico ADMET分析.
主要成果:
- 与AG-120相比,确定了五种化学多样性的化合物 (XS-1-XS-5),预计具有稳定的结合模式和有利的发展能力.
- 残留水平分析突出了诸如His132等上下文依赖的对结合亲和力的贡献.
- 管道成功地加速了发现过程,同时保持了化学多样性.
结论:
- 综合BNN辅助的SBVS和生成设计管道有效地加速了选择性突变IDH1抑制剂的发现.
- 这种方法通过考虑不确定性和指导生成,提高了可行的候选药物的识别.
- 鉴定到的线索和结构-活性关系的见解为进一步开发针对IDH1-突变癌症的药物提供了坚实的基础.
相关概念视频
Structure-Activity Relationships and Drug Design
1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K


